Table 2.
Hyper-endemic (40+% nodule carriers) | Mass treatment (CDTI) |
Meso-endemic (20–39% nodule carriers) | |
Hypo-endemic (<20% nodule carriers) | Clinic-based treatment |
Non endemic | No treatment |
Hyper-endemic (40+% nodule carriers) | Mass treatment (CDTI) |
Meso-endemic (20–39% nodule carriers) | |
Hypo-endemic (<20% nodule carriers) | Clinic-based treatment |
Non endemic | No treatment |